Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03457844
- Locations
- 🇨🇳
Yihebali Chi, Beijing, Beijing, China
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT03456466
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Tolerance and Pharmacokinetics of TQ-B3233
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03453034
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
A New Drug Used for Advanced Cancer
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03447145
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03099330
- Locations
- 🇨🇳
Sun-Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03059797
- Locations
- 🇨🇳
The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03019276
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital,School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02996838
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT02944864
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02930317
- Locations
- 🇨🇳
Anhui provincial hospital, Hefei, Anhui, China
🇨🇳Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Second hospital of Shanxi Medical University, Taiyuan, Shanxi, China